Navigation Links
Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
Date:10/11/2011

SEATTLE, Oct. 11, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the first patients have been treated in the Company's Phase 3 clinical program evaluating OMS302 in intra-ocular lens replacement surgery. OMS302, one of Omeros' proprietary PharmacoSurgery™ products, is added to standard irrigation solution used during cataract and other lens replacement surgery to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain and inflammation.

This Phase 3 clinical program is enrolling both cataract surgery and refractive lens exchange patients. Two randomized, double-blind, placebo-controlled, multicenter trials are planned. The first trial is underway in North America, and data are expected in the first quarter of 2012.  Omeros plans to initiate the second trial following discussions with regulators to ensure that data collected meet European expectations for marketing approval. The co-primary endpoints for these trials – maintenance of intraoperative pupil dilation (mydriasis) and reduction of postoperative pain – are the same as those achieved in the recently completed 221-patient Phase 2b trial.

"OMS302 has the potential to represent a significant advance for both ophthalmologic surgeons and their patients," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "The pace of enrollment to date has exceeded our expectations, and we look forward to announcing data from this program early next year."

Omeros' OMS302 Program

OMS302 is Omeros' PharmacoSurgery™ product candidate being developed for use during ophthalmological procedures including cataract and other lens replacement surgery. OMS302 is a proprietary combination of an anti-inflammatory active pharmaceutical ingredient (API) and an API that causes mydriasis (pupil dilation), each with we
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
(Date:1/14/2014)... a manufacturer of ergonomically designed laboratory equipment for research, ... Japan to sell and service the Hitachi brand ... utilize its network of sales professionals throughout the United ... assistance in application use, product benefits and features, options and accessories, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... First Commercial Market to Demonstrate Test,s Potential for ... ... ASA (OSL: DIAG) and Applied Biosystems Inc. (NYSE: ABI ) today,announced ... The test searches for a unique gene expression signature,identified by DiaGenic using ...
... Drug was Well-Tolerated, Significantly Inhibited ... on Monday, November 10 at 8:30 ... a.m. ET-, ... VIAP ), a biotechnology company focused on,the development of compounds for the treatment ...
Cached Medicine Technology:Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 2Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 3VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 2VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 3VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 4VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 5VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 6VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 7VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 8
(Date:4/18/2014)... Harvard neuroscientists have made a discovery that turns 160 ... electrical insulating material long known to be essential for ... nerve cells, is not as ubiquitous as thought, according ... of the Harvard Stem Cell Institute (HSCI) and the ... collaboration with Professor Jeff Lichtman, of Harvard,s Department of ...
(Date:4/18/2014)... your worst memories? How did it make you feel? ... negative personal experience, such as how sad you were ... distress, especially when you can,t stop thinking about it. ... about the context of the memories, rather than how ... to alleviate the negative effects of these memories, a ...
(Date:4/18/2014)... Simon Fraser University psychologists have made a brain-related ... of attention-deficit disorders. , This discovery opens up ... hinder or suppress a specific brain activity that ... distraction. , The Journal of Neuroscience ... by John McDonald, an associate professor of psychology ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... potential role of Eph receptor and ephrin ligand family ... other Eph receptors, EphA4 is distinguished by its ability ... type B ephrins. EphA4 reportedly forms a hetero receptor ... downstream signal transduction. However, alterations of EphA4 are not ...
... association of DM2 with solid tumors, and particularly with ... reported increased mortality rates for neoplastic diseases in patients ... diabetes and development of HCC, and the clinical and ... not been well examined. , A research article to ...
... 29 Abbott (NYSE: ABT ),will present at ... Nov. 12. Thomas C. Freyman, executive vice president, finance,and ... company at 5,p.m. CST., A live audio webcast ... Web site at http://www.abbottinvestor.com . An,archived edition of ...
... PRUSSIA, Pa., Oct. 29 HighPoint,Solutions LLC, a premier ... of its growth strategy, it has expanded its,presence in ... new location will,be at 8750 W. Bryn Mawr, Suite ... located near O,Hare International,Airport., Glenn Becker, HighPoint Solutions, ...
... N.J., Oct. 29 Derma Sciences, Inc.,(OTC Bulletin Board: ... it will present at the upcoming Rodman & Renshaw ... Palace Hotel in,New York City. The Company is scheduled ... Adams room located on the 4th floor., Management ...
... Drive Company,s Latest Learning Technology, ORLANDO, Fla., ... a leading provider of educational enterprise technology,announced today ... Release 9.0,featuring nearly 50 institutions that are now ... of the Beta program are evaluating and providing ...
Cached Medicine News:Health News:If the diabetes has a direct carcinogenetic effect? 2Health News:HighPoint Solutions Expands with New Chicago Office 2Health News:Derma Sciences to Present at The Rodman & Renshaw 10th Annual Healthcare Conference 2Health News:Blackboard Announces Launch of Beta Program 2Health News:Blackboard Announces Launch of Beta Program 3Health News:Blackboard Announces Launch of Beta Program 4
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Used for emergency airway access when conventional endotracheal intubation cannot be performed....
... Standard/Conventional. Stainless steel. Lamp supplied with ... high quality standard incandescent laryngoscope blades. The ... refined through many years of use the ... are manufactured to exacting specifications from the ...
... Blade. Stainless Steel. Lamp supplied with ... of high quality standard incandescent laryngoscope ... have been continually refined through many ... to minimize maintenance requirements. They are ...
Medicine Products: